🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, BGB-11417, DEXAMETHASONE , Kyprolis 60 mg powder for solution for infusion

    BEONE MEDICINES AUS PTY LTD

    relapsed or refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  2. Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, AZD0171, Oleclumab, Mycophenolate Mofetil 250 mg Capsules, Inflectra 100 mg powder for concentrate for solution for infusion, CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., volrustomig, CISPLATIN , Monalizumab, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, Rilvegostomig, Inflectra 100 mg powder for concentra

    AstraZeneca AB

    Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection in pre-filled syringe, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, REGN7508

    Lacuna Pharma Pty Ltd

    Thromboembolic disease

    phase 2 small molecule active

    1 trial

  4. Inlyta 1 mg film-coated tablets, Inlyta 3 mg film-coated tablets, CELLTOP 50 mg, capsule molle, ETOPOSIDE VIATRIS 20 mg/ml, solution à diluer pour perfusion

    ISTA Pharma Limited

    Ependymoma, Medulloblastoma

    phase 2 small molecule active

    1 trial

  5. Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab

    The George Institute

    Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  6. Irinotecan Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, PALBOCICLIB, Palbociclib, TEMOZOLOMIDE, TEMOZOLOMIDE, PALBOCICLIB, PALBOCICLIB, TEMOZOLOMIDE, Temozolomide SUN 5 mg hard capsules, Endoxan®, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion

    Pfizer Australia Pty Ltd

    recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastoma

    phase 2 small molecule active

    1 trial

  7. Isatuximab, Kyprolis 60 mg powder for solution for infusion, METHYLPREDNISOLONE , MONTELUKAST , DexaGalen® 8 mg injekt Injektionslösung, DIPHENHYDRAMINE , Dexamethason 4 mg JENAPHARM®, Dr. Reddy's Carfilzomib, PARACETAMOL

    Sanofi-aventis Healthcare Pty Ltd

    Cancer - Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  8. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Rectal

    phase 2 small molecule active

    1 trial

  9. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 2 small molecule active

    1 trial

  10. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    MMRd/MSI-H stage II-III endometrial cancer

    phase 2 small molecule active

    1 trial

  11. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  12. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Relapsed/Refractory Tumors

    phase 2 small molecule active

    1 trial

  13. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Cervical cancer

    phase 2 small molecule active

    1 trial

  14. JEMPERLI 500 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  15. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets

    The George Institute

    DNA repair-deficient or platinum-sensitive solid tumors

    phase 2 small molecule active

    1 trial

  16. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets

    Fondazione Telethon ETS

    HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  17. JNJ-54767414, Lenalidomide Accord 25 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, Dexamethasone Tablets BP 2.0mg, FLUDARABINE , Lenalidomide Accord 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Accord 15 mg hard capsules, JNJ-68284528, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 25 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Lenalidomide Accord 15 mg hard c

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  18. JNJ-64407564, RoActemra 20 mg/mL concentrate for solution for infusion, JNJ-64407564, JNJ-64407564, Tyenne 20 mg/ml concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Tyenne 20 mg/ml concentrate for solution for infusion, JNJ-64407564

    Janssen-Cilag International N.V.

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  19. JNJ-73841937, JNJ-61186372, Zirabev 25 mg/ml concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.

    phase 2 small molecule active

    1 trial

  20. JNJ-80202135, JNJ-80202135, Saline, 0.9% Sodium Chloride Solution for Injection

    Janssen-Cilag International N.V.

    Active Idiopathic Inflammatory Myopathies (IIM)

    phase 2 small molecule active

    1 trial

  21. JNJ-95475939, Placebo JNJ-95475939, Dupixent 300 mg solution for injection in pre-filled syringe

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    Squamous cell carcinoma of vulva/vagina, Squamous cell carcinoma of the head and neck, Squamous cell carcinoma of penis, Squamous cell carcinoma of cervix, Squamous cell carcinoma of anus

    phase 2 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Recurrent, platinum-resistant, CPS >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients

    phase 2 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    Patients with pre neoplastic high grade HPV-related vulvar and cervical lesions

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources